Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Trial Profile

Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Everolimus (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole; Tamoxifen; Toremifene
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.
    • 10 Mar 2017 Planned End Date changed from 1 May 2018 to 1 Jun 2018.
    • 10 Mar 2017 Planned primary completion date changed from 1 May 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top